Clinical Trial Update: Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

View source ↗

Summary

A Boston University–sponsored Merck study evaluating vorinostat for pruritus signaling pathways has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pruritus

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: Boston University | Conditions: Pruritus | Status: WITHDRAWN